IP Library Granted Patent US 8,244,345
Granted Patent B2
US 8,244,345 · App. 11/111,423 · Granted Aug 14, 2012

Treating a tumor or the like with electric fields at different frequencies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,244,345
App. No.
11/111,423
Granted
Aug 14, 2012
Kind
B2
Abstract

Cells that are in the late anaphase or telophase stages of cell division are vulnerable to damage by AC electric fields that have specific frequency and field strength characteristics. The selective destruction of rapidly dividing cells can therefore be accomplished by imposing an AC electric field in a target region for extended periods of time. Some of the cells that divide while the field is applied will be damaged, but the cells that do not divide will not be harmed. This selectively damages rapidly dividing cells like tumor cells, but does not harm normal cells that are not dividing. Improved results may be achieved by using a field with two or more frequencies.

Claims (63)

1. A method of selectively destroying or inhibiting the growth of rapidly dividing cells located within a target region of a patient, comprising the steps of:

(a) imposing a first AC electric field in the target region of the patient, the first electric field having a first frequency, wherein the first electric field has frequency characteristics that correspond to a vulnerability of the rapidly dividing cells, wherein the first electric field is strong enough to damage, during late anaphase or telophase stages of cell division, a significant portion of the rapidly dividing cells whose long axis is generally aligned with lines of force of the first electric field, and wherein the first electric field leaves non-dividing cells located within the target region substantially unchanged;

(b) imposing a second AC electric field in the target region of the patient, the second electric field having a second frequency that is different from the first frequency, wherein the second electric field has frequency characteristics that correspond to a vulnerability of the rapidly dividing cells, wherein the second electric field is strong enough to damage, during the late anaphase or telophase stages of cell division, a significant portion of the rapidly dividing cells whose long axis is generally aligned with lines of force of the second electric field, and wherein the second electric field leaves non-dividing cells located within the target region substantially unchanged; and

(c) repeating steps (a) and (b) until a therapeutically significant portion of the rapidly dividing cells die,

wherein step (a) is implemented during a first interval of time and step (b) is implemented during a second interval of time, wherein the first interval of time and the second interval of time are mutually exclusive, and wherein the frequencies of the first and second electric fields are between about 50 kHz and about 500 kHz.

2. The method of claim 1 , wherein the first and second electric fields are imposed in the target region via insulated electrodes.

3. The method of claim 1 , wherein the strength of the first and second electric fields in at least a portion of the target region is between about 0.1 V/cm and about 10 V/cm.

4. The method of claim 1 , wherein the frequencies of the first and second electric fields are between about 100 kHz and about 300 kHz.

5. The method of claim 4 , wherein the strength of the first and second electric fields in at least a portion of the target region is between about 1 V/cm and about 5 V/cm.

6. The method of claim 1 , wherein the frequency of the first electric field is about 170 kHz and the frequency of the second electric field is about 250 kHz.

7. The method of claim 6 , wherein the strength of the first and second electric fields in at least a portion of the target region is between about 1 V/cm and about 5 V/cm.

8. A method of selectively destroying or inhibiting the growth of rapidly dividing cells located within a target region of a patient, comprising the steps of:

(a) imposing a first AC electric field in the target region of the patient, the first electric field having a first frequency, wherein the first electric field has frequency and amplitude characteristics that cause the first electric field to selectively damage cells that are undergoing cell division and leave cells that are not undergoing cell division substantially unharmed;

(b) imposing a second AC electric field in the target region of the patient, the second electric field having a second frequency that is different from the first frequency, wherein the second electric field has frequency and amplitude characteristics that cause the second electric field to selectively damage cells that are undergoing cell division and leave cells that are not undergoing cell division substantially unharmed; and

(c) repeating steps (a) and (b) until a therapeutically significant portion of the rapidly dividing cells die,

wherein step (a) is implemented during a first interval of time and step (b) is implemented during a second interval of time, wherein the first interval of time and the second interval of time are mutually exclusive, and wherein the frequencies of the first and second electric fields are between about 50 kHz and about 500 kHz.

9. The method of claim 8 , wherein the first and second electric fields are imposed in the target region via insulated electrodes.

10. The method of claim 8 , wherein the strength of the first and second electric fields in at least a portion of the target region is between about 0.1 V/cm and about 10 V/cm.

11. The method of claim 8 , wherein the frequencies of the first and second electric fields are between about 100 kHz and about 300 kHz.

12. The method of claim 11 , wherein the strength of the first and second electric fields in at least a portion of the target region is between about 1 V/cm and about 5 V/cm.

13. The method of claim 8 , wherein the frequency of the first electric field is about 170 kHz and the frequency of the second electric field is about 250 kHz.

14. The method of claim 13 , wherein the strength of the first and second electric fields in at least a portion of the target region is between about 1 V/cm and about 5 V/cm.

15. A method of selectively destroying or inhibiting the growth of rapidly dividing cells located within a target region of a patient, comprising the steps of:

subjecting a target region to AC electric fields at a plurality of different frequencies, wherein the electric fields have frequency and field strength characteristics that cause the electric fields to selectively damage cells that are undergoing cell division, and wherein the electric fields leave cells that are not undergoing cell division substantially unharmed; and

repeating the subjecting step until a therapeutically significant portion of the rapidly dividing cells die,

wherein the electric fields at the plurality of different frequencies are applied sequentially, and wherein the frequencies of the electric fields are between about 50 kHz and about 500 kHz.

16. The method of claim 15 , wherein the target region is subjected to the electric fields via insulated electrodes.

17. The method of claim 15 , wherein the strength of the electric fields in at least a portion of the target region is between about 0.1 V/cm and about 10 V/cm.

18. The method of claim 15 , wherein the frequencies of the electric fields are between about 100 kHz and about 300 kHz.

19. The method of claim 18 , wherein the strength of the electric fields in at least a portion of the target region is between about 1 V/cm and about 5 V/cm.

20. A method of selectively destroying or inhibiting the growth of rapidly dividing cells located within a target region of a patient, comprising the steps of:

(a) imposing a first AC electric field in the target region of the patient, the first electric field having a first frequency, wherein the first electric field has frequency characteristics that correspond to a vulnerability of the rapidly dividing cells, wherein the first electric field is strong enough to damage, during late anaphase or telophase stages of cell division, a significant portion of the rapidly dividing cells whose long axis is generally aligned with lines of force of the first electric field, and wherein the first electric field leaves non-dividing cells located within the target region substantially unchanged;

(b) imposing a second AC electric field in the target region of the patient, the second electric field having a second frequency that is different from the first frequency, wherein the second electric field has frequency characteristics that correspond to a vulnerability of the rapidly dividing cells, wherein the second electric field is strong enough to damage, during the late anaphase or telophase stages of cell division, a significant portion of the rapidly dividing cells whose long axis is generally aligned with lines of force of the second electric field, and wherein the second electric field leaves non-dividing cells located within the target region substantially unchanged; and

(c) repeating steps (a) and (b) until a therapeutically significant portion of the rapidly dividing cells die,

wherein step (a) and step (b) are implemented simultaneously.

21. The method of claim 20 , wherein the first and second electric fields are imposed in the target region via insulated electrodes.

22. The method of claim 20 , wherein the frequencies of the first and second electric fields are between about 50 kHz and about 500 kHz.

23. The method of claim 22 , wherein the strength of the first and second electric fields in at least a portion of the target region is between about 0.1 V/cm and about 10 V/cm.

24. The method of claim 20 , wherein the frequencies of the first and second electric fields are between about 100 kHz and about 300 kHz.

25. The method of claim 24 , wherein the strength of the first and second electric fields in at least a portion of the target region is between about 1 V/cm and about 5 V/cm.

26. The method of claim 20 , wherein the frequency of the first electric field is about 170 kHz and the frequency of the second electric field is about 250 kHz.

27. The method of claim 26 , wherein the strength of the first and second electric fields in at least a portion of the target region is between about 1 V/cm and about 5 V/cm.

28. A method of selectively destroying or inhibiting the growth of rapidly dividing cells located within a target region of a patient, comprising the steps of:

(a) imposing a first AC electric field in the target region of the patient, the first electric field having a first frequency, wherein the first electric field has frequency and amplitude characteristics that cause the first electric field to selectively damage cells that are undergoing cell division and leave cells that are not undergoing cell division substantially unharmed;

(b) imposing a second AC electric field in the target region of the patient, the second electric field having a second frequency that is different from the first frequency, wherein the second electric field has frequency and amplitude characteristics that cause the second electric field to selectively damage cells that are undergoing cell division and leave cells that are not undergoing cell division substantially unharmed; and

(c) repeating steps (a) and (b) until a therapeutically significant portion of the rapidly dividing cells die,

wherein step (a) and step (b) are implemented simultaneously.

29. The method of claim 28 , wherein the first and second electric fields are imposed in the target region via insulated electrodes.

30. The method of claim 28 , wherein the frequencies of the first and second electric fields are between about 50 kHz and about 500 kHz.

31. The method of claim 30 , wherein the strength of the first and second electric fields in at least a portion of the target region is between about 0.1 V/cm and about 10 V/cm.

32. The method of claim 28 , wherein the frequencies of the first and second electric fields are between about 100 kHz and about 300 kHz.

33. The method of claim 32 , wherein the strength of the first and second electric fields in at least a portion of the target region is between about 1 V/cm and about 5 V/cm.

34. The method of claim 28 , wherein the frequency of the first electric field is about 170 kHz and the frequency of the second electric field is about 250 kHz.

35. The method of claim 34 , wherein the strength of the first and second electric fields in at least a portion of the target region is between about 1 V/cm and about 5 V/cm.

36. A method of selectively destroying or inhibiting the growth of rapidly dividing cells located within a target region of a patient, comprising the steps of:

subjecting a target region to AC electric fields at a plurality of different frequencies, wherein the electric fields have frequency and field strength characteristics that cause the electric fields to selectively damage cells that are undergoing cell division, and wherein the electric fields leave cells that are not undergoing cell division substantially unharmed; and

repeating the subjecting step until a therapeutically significant portion of the rapidly dividing cells die,

wherein the electric fields at the plurality of different frequencies are applied simultaneously.

37. The method of claim 36 , wherein the target region is subjected to the electric fields via insulated electrodes.

38. The method of claim 36 , wherein the frequencies of the electric fields are between about 50 kHz and about 500 kHz.

39. The method of claim 38 , wherein the strength of the electric fields in at least a portion of the target region is between about 0.1 V/cm and about 10 V/cm.

40. The method of claim 36 , wherein the frequencies of the electric fields are between about 100 kHz and about 300 kHz.

41. The method of claim 40 , wherein the strength of the electric fields in at least a portion of the target region is between about 1 V/cm and about 5 V/cm.

Assignments (17)
PATENT SECURITY AGREEMENT Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2024
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NOVOCURE GMBH
Reel/Frame 067211/0839 →
SECURITY INTEREST Recorded Nov 6, 2020
From: NOVOCURE GMBH
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 054344/0510 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 45278 0825 Recorded Aug 25, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 053597/0335 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 50395/0398 Recorded Aug 19, 2020
From: BPCR LIMITED PARTNERSHIP
To: NOVOCURE GMBH
Reel/Frame 053538/0623 →
OMNIBUS CONFIRMATION OF ASSIGNMENT AGREEMENT Recorded May 21, 2020
From: BIOPHARMA CREDIT PLC
To: BPCR LIMITED PARTNERSHIP
Reel/Frame 052741/0173 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 045278/0825 Recorded Apr 14, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 052391/0549 →
RELEASE OF SECURITY INTEREST Recorded Apr 13, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 052383/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2019
From: NOVOCURE LIMITED
To: NOVOCURE GMBH
Reel/Frame 050110/0098 →
SECURITY INTEREST Recorded May 6, 2019
From: NOVOCURE GMBH
To: BIOPHARMA CREDIT PLC
Reel/Frame 050395/0398 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045278/0825 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2018
From: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP
To: NOVOCURE LIMITED
Reel/Frame 044858/0416 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045284/0851 →
SECURITY INTEREST Recorded Feb 2, 2015
From: NOVOCURE LIMITED
To: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP
Reel/Frame 034866/0402 →
RELEASE OF SECURITY INTEREST Recorded Dec 20, 2013
From: DEUTSCHE BANK TRUST COMPANY AMERICAS
To: NOVOCURE LIMITED
Reel/Frame 031866/0567 →
SECURITY AGREEMENT Recorded Feb 20, 2013
From: NOVOCURE LIMITED
To: DEUTSCHE BANK TRUST COMPANY AMERICAS
Reel/Frame 029845/0135 →
CHANGE OF NAME Recorded Jul 11, 2012
From: STANDEN LIMITED
To: NOVOCURE LIMITED
Reel/Frame 028527/0432 →